deaths (OS)progression or deaths (PFS)RFS/DFS

mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 - certainty unassessablestatistically conclusive-37%-